ChemoCentryx to Hold Third Quarter 2021 Financial Results Conference Call on Tuesday, November 9, 2021

Rhea-AI Summary

ChemoCentryx, Inc. (Nasdaq: CCXI) will release its third quarter 2021 financial results after market close on November 9, 2021. A conference call with management will follow at 5:00 p.m. ET on the same day to discuss the results and address questions. Investors can access the live and archived audio webcast on the company’s website for 14 days post-call. ChemoCentryx is known for developing medications for inflammatory and autoimmune diseases, notably TAVNEOS, the first approved oral inhibitor for treating severe active ANCA-associated vasculitis.

Positive

• Scheduled release of Q3 2021 financial results, indicating transparency and engagement with investors.

Negative

• None.

MOUNTAIN VIEW, Calif., Nov. 02, 2021 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc., (Nasdaq: CCXI), today announced that the Company's third quarter 2021 financial results will be released after market close on Tuesday, November 9, 2021. ChemoCentryx executive management will host a conference call and webcast beginning at 5:00 p.m. Eastern Time on November 9, 2021 to discuss these results and to answer questions.

To participate by telephone, please dial (877) 303-8028 (Domestic) or (760) 536-5167 (International). The conference ID number is 7270887. A live and archived audio webcast can be accessed through the Investors section of the Company's website at www.ChemoCentryx.com. The archived webcast will remain available on the Company's website for fourteen (14) days following the call.

About ChemoCentryx
ChemoCentryx is a biopharmaceutical company commercializing and developing new medications for inflammatory and autoimmune diseases and cancer. ChemoCentryx targets the chemokine and chemoattractant systems to discover, develop and commercialize orally-administered therapies. In the United States, ChemoCentryx markets TAVNEOS^TM (avacopan), the first approved orally-administered inhibitor of the complement 5a receptor as an adjunctive treatment for adult patients with severe active ANCA-associated vasculitis. TAVNEOS is also in late-stage clinical development for the treatment of severe Hidradenitis Suppurativa and C3 glomerulopathy (C3G). Additionally, ChemoCentryx has early-stage drug candidates that target chemoattractant receptors in other inflammatory and autoimmune diseases and in cancer. For more information visit www.chemocentryx.com

Contacts:

Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com                                

Media:
Stephanie Tomei
408.234.1279
media@chemocentryx.com

Investors:
Lee Roth, Burns McClellan
212.213.0006
lroth@burnsmc.com

FAQ

When will ChemoCentryx release its Q3 2021 financial results?

ChemoCentryx will release its Q3 2021 financial results after market close on November 9, 2021.

What time is the conference call for ChemoCentryx's Q3 2021 results?

The conference call will begin at 5:00 p.m. Eastern Time on November 9, 2021.

How can I access the ChemoCentryx conference call?

The conference call can be accessed by dialing (877) 303-8028 for domestic calls or (760) 536-5167 for international calls, using the conference ID number 7270887.

Where can I find the archived audio webcast of the ChemoCentryx call?

The archived audio webcast will be available on ChemoCentryx's website for 14 days following the call.

What is TAVNEOS and what role does it play for ChemoCentryx?

TAVNEOS is ChemoCentryx's first approved orally-administered inhibitor for the treatment of severe active ANCA-associated vasculitis.